Understand the source comparison
Growth Hormone Secretagogues vs Direct Lipolytic Peptides
CJC-1295 with DAC (Drug Affinity Complex) extends the half-life of growth hormone-releasing hormone (GHRH) from 7 minutes to approximately 8 days, maintaining elevated plasma GH levels throughout the dosing interval. This produces sustained lipolysis through β
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- CJC-1295 with DAC (Drug Affinity Complex) extends the half-life of growth hormone-releasing hormone (GHRH) from 7 minutes to approximately 8 days, maintaining elevated plasma GH levels throughout the dosing interval. This produces sustained lipolysis through β-adrenergic receptor activation in adipocytes. The same pathway activated by catecholamines during fasted-state exercise. A 2012 study in the Journal of Clinical Endocrinology & Metabolism found CJC-1295 increased 24-hour mean GH levels by 200–400% without the pulsatile spikes that cause insulin resistance. The practical implication: researchers studying metabolic adaptation during prolonged caloric deficit can use CJC-1295 to maintain lipolytic signaling without triggering compensatory glucose dysregulation.
- AOD-9604 works through an entirely different mechanism. It's a C-terminal fragment of hGH (amino acids 176-191) that retains the fat-reducing properties of full-length GH without binding to the GH receptor that mediates glucose and IGF-1 effects. In vitro studies published in Hormone and Metabolic Research demonstrated AOD-9604 stimulates lipolysis in isolated adipocytes through direct activation of HSL and inhibition of lipogenesis. The synthesis of new fat from carbohydrates. The selectivity matters: visceral adipose tissue expresses higher HSL density than subcutaneous fat, which is why AOD-9604 produces disproportionate VAT reduction in clinical trials. Researchers examining visceral fat accumulation independent of total body weight can use AOD-9604 to isolate lipolytic effects without confounding variables from GH's anabolic or glucose-modulating actions.
- Our team has found that combining GHRH analogs with direct lipolytic agents produces additive effects in protocols targeting both subcutaneous and visceral fat depots simultaneously. CJC-1295 amplifies endogenous GH pulses that drive whole-body lipolysis, while AOD-9604 provides targeted HSL activation in VAT. Addressing both systemic energy deficit and localized adipose resistance within a single research design.